An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Immuron CEO, Steven Lydeamore Investor Webinar Presentation
Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary
Immuron Limited (IMC; IMRN) invites shareholders to attend an investor webinar 'Coffee Microcaps Morning Meeting' on November 30, 2023. CEO Steven Lydeamore will provide an update on the business and upcoming milestones, followed by a Q&A session.
Positive
None.
Negative
None.
MELBOURNE, Australia, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to invite shareholders to attend an investor webinar “Coffee Microcaps Morning Meeting”, to be held on Thursday, 30th of November, 2023, 9:00am ADEST.
CEO Steven Lydeamore will provide an overview and update on the business and upcoming milestones.
Following the presentation, attendees will have the opportunity to ask questions directly to Mr Lydeamore during a moderated Q & A session.
This webinar can be viewed live via zoom & you register via the link below.
Authorised for release by the Board of Immuron Limited.
COMPANY CONTACT: Steven Lydeamore Chief Executive Officer Ph: +61 (0)3 9824 5254 info@immuron.com
About Immuron
Immuron Limited (ASX: IMC, NASDAQ: IMRN) is an Australian biopharmaceutical company focused on developing and commercialising orally delivered targeted polyclonal antibodies for the treatment of infectious diseases.
immuron ltd is a publicly listed australian biopharmaceutical company focused on oral immunotherapy utilizing polyclonal antibody products that target the human gut immune system and gut microbiome. immuron’s technology platform is capable of developing and producing an orally stable therapeutic as a potential ‘oral targeted therapy’ for various immune mediated and inflammatory disorders, among them: non-alcoholic steatohepatitis (nash) diabetes, colitis, arthritis, inflammatory bowel diseases (ibd), irritable bowel syndrome (ibs), liver fibrosis and other chronic disorders in which the immune system plays a key role in thier pathogenesis. these disorders represent areas of growing and unmet medical need, where oral targeted therapy drugs could offer significant advantages due to the lack of absorption and the high safety profile. immuron has one marketed product, which provides proof of concept for its oral immune technology platform, and a pipeline of products at various stages of cl
